LEGN - מכפיל מחיר להכנסות עתידי Legend Biotech Corp.

Geographic reach across the US, Europe, and China creates a robust foundation for the expansion of Legend Biotech (LEGN). The forward P/S ratio confirms this trend, where 2.60 reflects the baseline level of the metric. Growth is supported by alliances with global pharma behemoths and the high cost of innovative treatments, which are consistently reimbursed by insurance companies.

The forward P/S reflects the ratio of current market value to expected revenue, allowing for an assessment of the investor's premium paid for potential revenue growth amid uncertainty. By analyzing the forward price-to-sales ratio, one can evaluate the capitalization stability of Legend Biotech (LEGN), based on the commercial success of Carvykti CAR-T therapy and the strategic alliance with J&J, which ensures the scaling of sales.